Scott B. Ullem Sells 11,250 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Edwards Lifesciences Trading Up 0.3 %

EW opened at $76.23 on Friday. The company’s 50 day moving average is $72.58 and its 200-day moving average is $69.41. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market cap of $44.96 billion, a P/E ratio of 11.00, a PEG ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Equities research analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently made changes to their positions in the stock. Prosperity Consulting Group LLC boosted its position in shares of Edwards Lifesciences by 3.6% in the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company’s stock valued at $289,000 after acquiring an additional 134 shares during the period. Abacus Planning Group Inc. boosted its position in shares of Edwards Lifesciences by 0.3% in the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after acquiring an additional 140 shares during the period. Bowman & Co S.C. boosted its position in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after acquiring an additional 148 shares during the period. Moors & Cabot Inc. boosted its position in shares of Edwards Lifesciences by 0.3% in the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock valued at $4,041,000 after acquiring an additional 152 shares during the period. Finally, Quadrant Capital Group LLC boosted its position in shares of Edwards Lifesciences by 3.1% in the fourth quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company’s stock valued at $383,000 after acquiring an additional 156 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on EW. Barclays increased their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday. Truist Financial reaffirmed a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. The Goldman Sachs Group raised their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research report on Wednesday. Finally, Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.